|
[TECHNOLOGY
OPPORTUNITY 1996-002]
<<
Back to Life Sciences
Canine Factor VIII Gene, Protein and Use
1996-002
Description of the Technology:
Dr. David Lillicrap of the Department of Pathology at
Queen's University has developed a canine factor VIII
cDNA and constructed several B domain deleted forms
of this sequence.
The technology provides isolated nucleic acid molecules
encoding canine factor VIII and mutants, fragments and
derivatives thereof. The technology also provides canine
factor VIII polypeptides encoded by such isolated nucleic
acid molecules, antibodies binding to such polypeptides,
genetic constructs comprising such nucleic acid molecules,
prokaryotic or eukaryotic host cells or whole animals
comprising such genetic constructs, and methods and
compositions for use in diagnosing disorders characterized
by factor VIII deficiency, and therapeutic methods for
treating diseases characterized by factor VIII deficiency.
Benefits of the Technology:
• The technology provides methods useful during
diagnosis of a canine Factor VIII deficiency-dependent
bleeding disorder, and methods for treating a canine
afflicted with such a disorder.
• Since the identification of spontaneously occurring
hemophilia A in dogs, there has been increasing interest
in the use of canines as model systems for the study
of the physiology of human diseases such as hemophilia
A characterized by Factor VIII deficiencies. Furthermore,
the canine has shown promise as a model system for the
development of methods of detecting and treating such
diseases in humans.
Commercial Status:
PARTEQ has negotiated a number of non-exclusive licenses
with pharmaceutical companies interested in using the
canine factor VIII cDNA construct in their hemophilia
gene therapy development efforts. PARTEQ is currently
seeking additional licensees to further develop and
commercialize this technology. Dr. Lillicrap's research
group has access to a large colony of hemophilia A dogs
and considerable expertise in monitoring physiologic
and hemostatic outcomes in these animals.
Contact:
Perry M. Kim, Ph.D.
Manager, Commercial Development
tel: (613) 533-2342 fax: (613) 533-6853
pkim@parteqinnovations.com
|
